Tesamorelin 10 mg
research-grade
lyophilized peptide powder
in a glass vial. Tesamorelin (also known as TH9507) is a synthetic analog of human Growth Hormone-Releasing Hormone (GHRH), studied in experimental models of GH/IGF-1 axis modulation, visceral adiposity, lipodystrophy-like states and metabolic regulation.
Research Use Only:
All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
99%+ (HPLC, third-party tested)
Form
Lyophilized peptide powder
Content
10 mg Tesamorelin per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C in a dry, desiccated place, protected from light.
Molecular formula
C221H366N72O67S
Molecular weight
~5135.8 g·mol⁻¹
Sequence
(trans-3-hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC).
For a compatible research-only solvent, see
Bacteriostatic water – 10 ml
.
Research Overview
Tesamorelin (TH9507) is a synthetic peptide analog of human Growth Hormone-Releasing Hormone (GHRH) comprising the full 44-amino acid sequence of hGHRH with an N-terminal trans-3-hexenoyl modification that enhances stability and resistance to enzymatic degradation. In experimental systems, Tesamorelin is used as a tool compound to investigate regulation of the GH/IGF-1 axis, visceral adipose tissue dynamics, lipodystrophy-like phenotypes and broader metabolic and neuroendocrine pathways in vitro and in vivo research models.
Primary Research Areas
-
GH/IGF-1 axis and pituitary signaling:
Used in experimental models to study how GHRH analog stimulation influences pituitary growth hormone release, circulating IGF-1 levels and downstream anabolic and metabolic signaling cascades.
-
Visceral adipose tissue and lipodystrophy models:
Applied in preclinical research exploring alterations in visceral fat depots, abnormal fat distribution and associated metabolic parameters in lipodystrophy-like experimental paradigms.
-
Metabolic regulation and glucose–lipid interactions:
Employed to probe relationships between GH/IGF-1 signaling, glucose handling, lipid metabolism and insulin sensitivity in diverse metabolic research models.
-
Body composition and tissue remodeling:
Used in studies of lean mass, fat mass and tissue remodeling to characterize how chronic modulation of the GHRH–GH–IGF-1 axis impacts body composition in experimental systems.
-
Neuroendocrine and cognitive research:
Investigated in models assessing hypothalamic–pituitary regulation, neuroendocrine feedback loops and potential cognitive or brain-structure–related endpoints in aging or metabolic-stress paradigms.
